SCHEMBL10175698

SCHEMBL10175698

CC(Oc1ccc(O)cc1)C(=O)Nc1ccc(Cl)cc1

nearest known ligand 0.76

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.67
ALDH1A1 P00352 1/20 0.67
GAA P10253 1/20 0.67
KMT2A Q03164 7/20 0.58
MEN1 O00255 6/20 0.58
LMNA P02545 3/20 0.55
SCN3A Q9NY46 1/20 0.55
RXFP1 Q9HBX9 1/20 0.55
TDP1 Q9NUW8 1/20 0.53
POLB P06746 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
EPHX2 P34913 1/20 0.53
KLK7 P49862 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10175701 0.94 KMT2A (0.62) KDM4EALDH1A1GAAKMT2AMEN1
SCHEMBL10175705 0.88 MEN1 (0.67) ALDH1A1GAAKMT2AMEN1LMNA
SCHEMBL10175700 0.88 KMT2A (0.58) KDM4EALDH1A1GAAKMT2AMEN1
SCHEMBL2610070 0.87 LMNA (0.66) ALDH1A1KMT2AMEN1LMNASCN3A
SCHEMBL10175711 0.87 LMNA (0.71) KDM4EALDH1A1GAAKMT2AMEN1
SCHEMBL10175704 0.87 KMT2A (0.57) KDM4EALDH1A1GAAKMT2AMEN1
SCHEMBL2610073 0.87 KMT2A (0.72) KMT2AMEN1RXFP1POLBL3MBTL1
SCHEMBL2610075 0.87 KMT2A (0.72) KMT2AMEN1RXFP1POLBL3MBTL1
SCHEMBL10175696 0.87 KMT2A (0.63) ALDH1A1KMT2AMEN1LMNARXFP1
SCHEMBL10175988 0.87 KMT2A (0.72) KMT2AMEN1RXFP1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150099781-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-04-09 US disclosed
US-8969342-B2 Compounds and methods for treating mammalian gastrointestinal microbial infections BRANDEIS UNIVERSITY (US) 2015-03-03 US disclosed
US-20120101096-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections University of Georgia Foundation, Inc. (US) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101096-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections IMPDH1, IMPDH2, IMPA1 KDM4E 1620/4885ALDH1A1 45/4885GAA 264/4885
US-20150099781-A1 Compounds and Methods for Treating Mammalian Gastrointestinal Microbial Infections IMPDH1, IMPDH2, IMPA1 KDM4E 1620/4885ALDH1A1 45/4885GAA 264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.